Automating Prior Authorizations for Dermatology MCG Criteria

Navigating prior authorizations for dermatology often involves complex medical necessity reviews based on MCG criteria. Klivira automates the validation and submission process to accelerate approvals for high-cost biologics and Mohs surgery.

For revenue cycle directors and prior authorization coordinators in dermatology, managing the volume and complexity of PAs can significantly impact patient access and practice efficiency. Adherence to payer-mandated MCG criteria for biologics, specialty topicals, and Mohs procedures is critical, yet manual processes frequently lead to delays and denials.

The Challenge of Dermatology MCG Criteria in Prior Authorization

Dermatology practices face unique prior authorization hurdles, particularly with high-cost biologics for conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa, as well as complex procedures such as Mohs micrographic surgery. Payers frequently rely on evidence-based medical necessity criteria, including those from MCG Health, to determine approval, demanding precise clinical documentation and adherence to step therapy protocols.

Key Dermatology Procedures and Medications Subject to MCG Review

Biologics for Psoriasis and Psoriatic Arthritis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi)
Biologics for Atopic Dermatitis and Hidradenitis Suppurativa
Mohs Micrographic Surgery for non-melanoma skin cancers in sensitive areas
Advanced Immunotherapy for Melanoma (e.g., Keytruda, Opdivo)
Home Phototherapy for chronic skin conditions

Meeting Documentation Requirements for MCG Criteria

Successful prior authorizations for dermatology services depend on submitting comprehensive documentation that aligns with both clinical guidelines and payer-specific MCG requirements. This often involves demonstrating medical necessity through specific disease severity scores (e.g., PASI, EASI, BSA), documenting trials of prior therapies (topicals, phototherapy, conventional systemics), and conforming to guidelines like the AAD Clinical Guidelines and NCCN for skin cancers.

Common Denial Reasons Related to MCG Criteria in Dermatology

Failure to document completion of required step therapy protocols for biologics
Insufficient documentation of disease severity (e.g., missing PASI, EASI, or BSA scores)
Mohs surgery indications not aligning with AAD Appropriate Use Criteria or payer policies
Gaps in pre-biologic screenings for conditions like TB or hepatitis
Non-compliance with biosimilar substitution policies

Klivira's Solution for Dermatology MCG Criteria Automation

Klivira's platform automates the intricate process of prior authorization for dermatology, specifically addressing MCG criteria. By integrating directly with EMRs via SMART on FHIR, our system applies AAD-guideline-aware step-therapy logic, validates Mohs surgery against Appropriate Use Criteria, and manages periodic re-authorization workflows. This ensures accurate submissions through X12 278 and payer portals, reducing manual effort and improving approval rates.

Frequently asked questions

How does Klivira handle specific MCG criteria for dermatology biologics?

Klivira's platform incorporates logic derived from AAD Clinical Guidelines to validate medical necessity for biologics used in psoriasis, atopic dermatitis, and hidradenitis suppurativa. This includes automating checks for documented disease severity, prior topical and systemic therapy trials, and compliance with step therapy requirements, aligning submissions with payer-mandated MCG criteria.

Can Klivira help with Mohs surgery prior authorizations subject to MCG?

Yes, Klivira supports Mohs micrographic surgery prior authorizations by validating procedure requests against AAD Appropriate Use Criteria (AUC) and payer-specific policies often informed by MCG. The system ensures that documentation for tumor type, site, and other indications is complete before submission, reducing denials related to AUC mismatches.

How does Klivira integrate with our EMR to gather dermatology-specific data for MCG?

Klivira integrates with your EMR using SMART on FHIR standards to extract relevant clinical data for dermatology prior authorizations. This includes patient demographics, diagnosis codes, procedure codes, medication history, and specific clinical notes like PASI/EASI scores, which are crucial for satisfying MCG criteria and supporting medical necessity.

What about re-authorizations for chronic dermatology treatments like biologics?

Klivira's platform includes features for managing periodic re-authorizations, a common requirement for chronic biologic treatments in dermatology. The system tracks re-authorization cycles, proactively alerts staff, and helps streamline the submission of updated clinical documentation to ensure continuous coverage for patients.

Does Klivira differentiate between medical and pharmacy benefit for dermatology drugs?

Yes, Klivira is designed to differentiate between medical and pharmacy benefit routing for dermatology medications, including self-injected biologics versus clinic-infused drugs. This ensures that prior authorization requests are sent through the correct payer channel (e.g., X12 278 for medical benefit, NCPDP SCRIPT for pharmacy benefit, or specific payer portals), preventing delays due to incorrect submission pathways.